Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin 2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).

Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin 2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).

The present invention provides a method for identifying a substance capable of inhibiting at least one activity of an RNA-dependent RNA polymerase (RdRp) comprised in an influenza viral ribonucleoprotein (RNP) complex, which method comprises or consists of: (a) providing an aqueous suspension of purified influenza virus comprising said RNP complex; (b) adding to said suspension of step (a) (i) a nonionic or zwitterionic surfactant; and (ii) a reducing agent; (c) incubating the mixture obtained in step (b) in order to obtain an influenza virus lysate; (d) contacting the influenza virus lysate obtained in step (c) with a test substance under conditions that permit said test substance to interact with said RdRp comprised in said RNP complex, said RNP complex being present in said influenza virus lysate; and (e) determining whether said test substance inhibits said at least one activity of said RdRp.

Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin 2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).

The present invention relates to a method and kit for removing linker self-linking products during sequencing library construction and for constructing a sequencing library. In particular, provided is a method and kit for the selective cleavage of DNA double strands and DNA single strands, a method and kit for selective cleavage by using DNA-RNA-DNA:cDNA heterozygous chains and DNA:cDNA double strands, and a method and kit for DNA and RNA library co-construction.